Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Strategies in antibody therapy of cancer.

× No keyword cloud information.

43 in total

1. A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates.

Authors: A M Montgomery; M G Wing; P J Lachmann
Journal: Clin Exp Immunol Date: 1990-11 Impact factor: 4.330

2. Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.

Authors: M Chiron; J P Jaffrezou; P Carayon; C Bordier; F Roubinet; C Xavier; M Brandely; G Laurent
Journal: Clin Exp Immunol Date: 1990-11 Impact factor: 4.330

3. Bispecific antibody that binds carcinoembryonic antigen and ricin toxin A chain cytotoxic for gastrointestinal tract tumor cells.

Authors: R A Robins; M J Embleton; M V Pimm; D S Betts; A Charleston; A J Markham; R W Baldwin
Journal: J Natl Cancer Inst Date: 1990-08-01 Impact factor: 13.506

Review 4. Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors: S Songsivilai; P J Lachmann
Journal: Clin Exp Immunol Date: 1990-03 Impact factor: 4.330

5. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.

Authors: M A Garrido; M J Valdayo; D F Winkler; J A Titus; T T Hecht; P Perez; D M Segal; J R Wunderlich
Journal: Cancer Res Date: 1990-07-15 Impact factor: 12.701

6. Cytostasis of different tumours by a murine PPD-reactive CD4+ T lymphocyte clone is mediated by interferon-gamma and tumour necrosis factor alone or synergistically.

Authors: M G Wing; A M Montgomery; C Harley; P J Lachmann
Journal: Clin Exp Immunol Date: 1990-11 Impact factor: 4.330

7. Suppression of well-established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine.

Authors: W Smith; V A Gore; D R Brandon; D N Lynch; S A Cranstone; J R Corvalan
Journal: Cancer Immunol Immunother Date: 1990 Impact factor: 6.968

8. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice.

Authors: J M Le Doussal; A Gruaz-Guyon; M Martin; E Gautherot; M Delaage; J Barbet
Journal: Cancer Res Date: 1990-06-01 Impact factor: 12.701

9. In vivo tumor targeting of a recombinant single-chain antigen-binding protein.

Authors: D Colcher; R Bird; M Roselli; K D Hardman; S Johnson; S Pope; S W Dodd; M W Pantoliano; D E Milenic; J Schlom
Journal: J Natl Cancer Inst Date: 1990-07-18 Impact factor: 13.506

10. A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.

Authors: M V Pimm; R A Robins; M J Embleton; E Jacobs; A J Markham; A Charleston; R W Baldwin
Journal: Br J Cancer Date: 1990-04 Impact factor: 7.640

2 in total

1. Comparison of the cellular internalization of antibodies used either as immunotoxins or in ADEPT.

Authors: D C Blakey; P E Pinder; A F Wright
Journal: Cell Biophys Date: 1994

Review 2. Systemic immunotoxin therapy of cancer: advances and prospects.

Authors: E J Wawrzynczak
Journal: Br J Cancer Date: 1991-10 Impact factor: 7.640

2 in total